Solid Biosciences: INSPIRE DUCHENNE Data and FDA Pathway Support Overweight/Buy Rating on SGT-003 Gene Therapy Upside

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SLDB stock, giving a Buy rating today.

Anupam Rama has given his Buy rating due to a combination of factors tied to the SGT-003 program’s emerging profile. He highlights that the latest INSPIRE DUCHENNE interim data show robust and durable microdystrophin expression at both 90 and 360 days, along with sustained improvements in muscle injury biomarkers and encouraging signals on cardiac measures, all consistent with earlier readouts.

He also notes that the safety profile remains manageable and in line with prior experience, without signals of serious liver or thrombotic complications that have challenged other gene therapies. In his view, this clinical consistency, combined with upcoming FDA interactions aimed at defining a potential accelerated approval pathway and additional pipeline upside beyond SGT-003, supports a favorable risk‑reward and justifies an Overweight/Buy stance on SLDB shares.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SLDB in relation to earlier this year.